英矽智能：与衡泰生物达成超过5亿港元的全球战略合作，共同开发新型血脑屏障穿透性NLRP3抑制剂

Core Viewpoint - Insilico Medicine has entered into a strategic partnership with Shenzhen Hengtai Biotechnology to jointly develop ISM8969, a novel oral NLRP3 inhibitor aimed at treating central nervous system diseases [1] Group 1: Partnership Details - The collaboration will accelerate the global development of ISM8969 [1] - Insilico Medicine grants Hengtai Biotechnology 50% rights for research, development, registration, production, and commercialization of ISM8969 worldwide [1] Group 2: Financial Terms - Insilico Medicine is set to receive over HKD 500 million in upfront and milestone payments [1] - An upfront payment of HKD 78 million is expected to be paid within 30 days of the agreement's effective date [1]